Inflammation Markers Don't Predict Erenumab's Migraine Success
- 6 days ago
- 1 min read
Research Summary
A recent study published in the European Journal of Neurology investigated whether serum inflammatory markers, specifically high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-alpha (TNF-α), are linked to the effectiveness of erenumab in preventing migraines. The study involved 679 adults who self-administered erenumab over 24 weeks. Although 52% experienced at least a 50% reduction in migraine days, neither hs-CRP nor TNF-α levels predicted treatment success. While TNF-α levels rose slightly during treatment, no significant differences were found between responders and non-responders. This suggests a need for more targeted biomarkers to improve personalized migraine therapies.
Study Details
👥 Research Team: Karlsson WK et al.
📚 Published In: Eur J Neurol
📅 Publication Date: 2026 Jul
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.